Luís Isidoro

MD, Neurologist

[Barry Singer MD 🧠 @drbarrysinger]

Phase III FENtrepid Study:
#Fenebritninb achieved noninferiority to ocrelizumab in reducing disability progression (cCDP12) in primary progressive multiple sclerosis #PPMS patients; actually 12% better. @ACTRIMS #ACTRIMSForum

[MSJ @MSJ_Research]

How do neurologists perceive the organization and functioning of #MultipleSclerosis care units? Enhancing care coordination could improve care delivery and mitigate the risk of burnout for clinicians.

🔓MSJ-ETC study from @Roche ▶️ https://t.co/ok0bnPr1bW

[Daniel Ontaneda @DanOntaneda]

Brand new MS diagnostic Criteria. Congratulations to @XMontalban and all involved. A huge step forward towards biologically based diagnosis of #MultipleSclerosis @ECTRIMS @ACTRIMS @mssociety @TheLancetNeuro

https://t.co/IQxJ45v7sQ

[Heinz Wiendl @hwiendl]

🚨 Paradigm shift in #MultipleSclerosis 🚨
New study in Nature Medicine shows MS is not fixed subtypes but a dynamic continuum of states across 4 dimensions: disability, brain damage, relapses & silent inflammation.

📖 Read: https://t.co/MYvAAI6AiV
#MS #Neurology #AI

[Eoin Flanagan @EoinFlanagan14]

Happy to share @albertaboseif et al multicenter study showing 4% of #MOGAD with meningitis ➡️ Frequent misdiagnosis as infection ➡️ Updates in criteria could incorporate this phenotype ➡️ Path had meningeal T & B cells, microglia & cortical myelin loss👇 https://t.co/7gn8z4HzhH

[Ahmed Y. Azzam, MD, MEng, DSc(h.c.), FRCP @AhmedYAzzam]

11.7 Tesla Brain MRI 🧠 !

First scans from the world's most powerful MRI scanner! 🔥

It costs around 75 million euros for the 11.7 Tesla MRI machine! 😮 😲

#brain #Neurology #mri #HealthAwareness #radiology

[ECTRIMS @ECTRIMS]

#ECTRIMS2024 | That's a wrap!

This year’s congress may be over, BUT the sharing of knowledge is definitely not 👇 👇 👇

The ECTRIMS 2024 Best of Slide Deck is now available. Download & share this valuable information with your colleagues and peers ➡️ https://t.co/LjcyuPdJfg

[Professor_Bart @bart_professor]

Nourbakhsh (US): prospective study on anti-CD20 ‘induction’ in RRMS:
6 months treatment only.
19 pts study…but nice results. Risk of reoccurrence of disease is higher in patients with central tolerance defect @baseline! B-cell return ‘as such’ is not predictive.
#ECTRIMS2024

[Professor_Bart @bart_professor]

Hogenboom (NL): first results of BLOOMS trial: standard vs extended interval dosing of ocrelizumab based on B-cell counts. No difference in efficacy (Relapses and MRI lesions)!
(Long term results to follow)
Big difference in intervals are seen (see slide)
#ECTRIMS2024

[Professor_Bart @bart_professor]

Fox Rob (US): tolebrutinib vs placebo in nrSPMS (HERCULES trial)
- 6m CDP: 31% decreases risk on tolebr
- 3m CDP: 24% “
- 6m CDI: increased chance on tolebr
- brain atrophy: no difference 🤔
Hopes are up for a change for persons with SPMS 🤞🏻👏🏻💪🏻
#ECTRIMS2024

[Suma Shah @sumadshah]

The summary: 6/6
#ECTRIMS2024

[Samer Salama @samer_salama]

@MHegazyMD @ECTRIMS

[Mohamed Hegazy @MHegazyMD]

McDonald Criteria 2024 @ECTRIMS @Multiple_Sclerosis

[Professor_Bart @bart_professor]

Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials).
- ARR : no difference!
- 6m CDW: 29% reduction on tolebr
- 3m CDW: 27% reduction on tolebr
- New Gd+ lesions are higher on tolebrutinib!
- T2 lesions: no difference
- good safety profile
#ECTRIMS2024

[Barry Singer MD 🧠 @drbarrysinger]

Encouraging topline results regarding #tolebrutinib! In Hercules trial, tolebrutinib delayed disability progression vs. placebo in secondary-progressive MS patients without relapses. Thanks to our center's patients that participated in the trials! https://t.co/0uIZCjyJBk

[Neurochecklists @neurochecklists]

Catch up with Stephen Hauser, #MultipleSclerosis neurologist and author of The Face Laughs While the Brain Cries

Apple: https://t.co/BCMQimGr2A
Spotify: https://t.co/vHd41hENpE
YouTube: https://t.co/lDe9f2wid7

[Luís Isidoro @lisidoro4]

@SoniaRMbatista Indeed!

[Luís Isidoro @lisidoro4]

Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions - Annals of Neurology https://t.co/rqPk7lw76f

[JAMA Neurology @JAMANeuro]

A new @JAMA_current study found a blood test had high diagnostic accuracy for identifying Alzheimer disease among adults with cognitive symptoms.

This test could lead to early diagnosis and may facilitate timely access to new treatments.

#AAIC24

https://t.co/FFwOm2jNrl

[Neurology Journal @GreenJournal]

Pourfour du Petit syndrome is a rare disorder with symptoms opposite of Horner syndrome, manifesting with unilateral mydriasis, hyperhidrosis, and eyelid retraction. Learn more in this #NeurologyRF e-Pearl: https://t.co/SSJ5hlaAEM